2023年1月19日

OcuSciences的旗艦設備，OcuMet Beacon，在遺傳性視網膜營養不良患者中檢測到比同齡對照組更高的黃蛋白熒光(FPF)——(美國商業資訊)——OcuSciences, Inc.是一家醫療設備公司，開發視網膜成像儀，通過評估視網膜代謝活動來檢測早期疾病，今天宣布在《眼科遺傳學》雜誌上發表一項罕見的遺傳性線粒體疾病研究。這些發現表明，新的FPF測量可以區分診斷為遺傳性視網膜營養不良的患者及其年齡匹配的對照組。此外，FPF結果與眼底自身熒光結果相關，提示快速、自動化測量的臨床應用價值。這項觀察性研究，由Elias Traboulsi博士領導，M.D。克利夫蘭診所科爾眼科研究所遺傳眼病中心主任，包括157例遺傳證實的杆狀錐營養不良、Stargardt病、bardt - biedl綜合征(BBS)和線粒體ATP合酶突變的患者。在2021年1月至12月期間，使用OcuSciences的旗艦功能性視網膜成像儀OcuMet Beacon對患者進行成像，以捕捉和量化他們的FPF信號。遺傳性視網膜營養不良患者的平均FPF強度和異質性明顯高於年齡匹配的對照組。Traboulsi博士說:“這些發現表明，黃蛋白熒光可以作為評估和診斷遺傳性視網膜營養不良患者的額外工具。”“需要更多的研究來幫助闡明這種成像方式如何在臨床上實施，以及是否有機會將FPF用作這類疾病的監測工具。” The OcuMet Beacon is an automated, rapid retinal imager that assesses mitochondrial function by interrogating flavoproteins. The device emits a very specific wavelength of light that selectively excites flavoproteins in retinal mitochondria that are dysfunctional and hence cannot efficiently produce ATP. The flavoproteins in dysfunctional mitochondria emit a specific wavelength that the device then captures and quantifies. Mitochondrial dysfunctional has been documented as a precursor to apoptosis, or cell death. The OcuMet Beacon is currently being used under Institutional Review Board at Cole Eye Institute. About OcuSciences, Inc. OcuSciences, Inc., is a commercial-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the early detection of disease. Its flagship device, the OcuMet Beacon, has being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluorescence (FPF), a well-studied precursor to retinal cell death, in a patient’s eye. OcuSciences has shown preliminary clinical utility in a number of different disease states, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Learn more at www.ocusciences.com . Contacts